
Metastatic Castration Resistant Prostate Cancer Market
Description
Metastatic Castration Resistant Prostate Cancer Market Report and Forecast 2024-2032
The metastatic castration-resistant prostate cancer market was valued at USD 11.1 billion in 2023, driven by the increasing prevalence of advanced prostate cancer and the growing demand for innovative therapies, including immunotherapies and targeted treatments. The market is expected to grow at a CAGR of 8.1% during the forecast period 2024-2032, reaching a market value of USD 22.4 billion by 2032.
Metastatic Castration Resistant Prostate Cancer Market Analysis
Metastatic castration-resistant prostate cancer (mCRPC) refers to an advanced stage of prostate cancer in which the disease spreads beyond the prostate gland to other parts of the body, such as the bones, lymph nodes, or organs. This condition persists even after lowering testosterone levels through medical or surgical means, a process known as castration, which is aimed at controlling the disease. Unfortunately, patients with metastatic castration-resistant prostate cancer continue to experience disease progression despite these interventions, making it a challenging condition to manage. Treatment options for metastatic castration-resistant prostate cancer focus on controlling tumour growth, relieving symptoms, and improving survival rates with chemotherapy, hormonal therapy, immunotherapy, and radiation therapy. The complexity of this condition makes it a key area of focus within cancer research and oncology treatment development.
Market Drivers
The metastatic castration-resistant prostate cancer market is evolving rapidly, driven by technological innovations and advancements in treatment approaches. As ongoing research provides new insights into disease management and therapeutic strategies, several key trends are emerging that are shaping the future direction of this market. These trends are expected to significantly impact the treatment landscape, improving patient outcomes and expanding access to more effective and personalised therapies.
Metastatic Castration Resistant Prostate Cancer Market Segmentation
Market Breakup by Treatment Type
Chemotherapy
Immunotherapy
Hormonal Therapy
Radiation Therapy
Others
The market is segmented by treatment type into chemotherapy, immunotherapy, hormonal therapy, radiation therapy, and others. Chemotherapy and hormonal therapy remain the most commonly used treatments for metastatic castration-resistant prostate cancer. However, immunotherapy is gaining prominence as a targeted treatment with fewer side effects, while radiation therapy continues to be used in specific cases to manage pain and symptoms.
Market Breakup by Route of Administration
Oral
Parenteral
Others
The market is segmented by route of administration into oral, parenteral, and others. Oral administration is commonly used for hormonal therapies and some targeted treatments, providing convenience for patients undergoing long-term treatment. Parenteral administration, which involves injections or intravenous delivery, is used for chemotherapy and immunotherapy, ensuring faster and more controlled drug absorption.
Market Breakup by End User
Market Breakup by Region
Metastatic Castration Resistant Prostate Cancer Market Competitive Landscape
The competitive landscape of the metastatic castration-resistant prostate cancer market includes major players such as AstraZeneca, Pfizer Inc., AB Science, Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, Daiichi Sankyo Inc., Teva Pharmaceutical Industries Ltd, Sanofi, and Eli Lilly and Company. These companies are focused on developing innovative treatments, including immunotherapies and targeted therapies, with strategic partnerships and clinical trials driving market expansion.
Key Questions Answered in the Report
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the metastatic castration resistant prostate cancer market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the metastatic castration resistant prostate cancer market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the metastatic castration resistant prostate cancer industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
The metastatic castration-resistant prostate cancer market was valued at USD 11.1 billion in 2023, driven by the increasing prevalence of advanced prostate cancer and the growing demand for innovative therapies, including immunotherapies and targeted treatments. The market is expected to grow at a CAGR of 8.1% during the forecast period 2024-2032, reaching a market value of USD 22.4 billion by 2032.
Metastatic Castration Resistant Prostate Cancer Market Analysis
Metastatic castration-resistant prostate cancer (mCRPC) refers to an advanced stage of prostate cancer in which the disease spreads beyond the prostate gland to other parts of the body, such as the bones, lymph nodes, or organs. This condition persists even after lowering testosterone levels through medical or surgical means, a process known as castration, which is aimed at controlling the disease. Unfortunately, patients with metastatic castration-resistant prostate cancer continue to experience disease progression despite these interventions, making it a challenging condition to manage. Treatment options for metastatic castration-resistant prostate cancer focus on controlling tumour growth, relieving symptoms, and improving survival rates with chemotherapy, hormonal therapy, immunotherapy, and radiation therapy. The complexity of this condition makes it a key area of focus within cancer research and oncology treatment development.
Market Drivers
- Rising Incidence of Prostate Cancer: The increasing prevalence of prostate cancer, particularly among the ageing male population, is driving the demand for effective treatments for advanced stages of the disease, including metastatic castration-resistant prostate cancer. With a growing number of men reaching older ages, the incidence of prostate cancer is expected to continue to rise, fuelling the market for innovative therapies aimed at managing this challenging condition.
- Advancements in Treatment Modalities: Significant advancements in treatment options for metastatic castration-resistant prostate cancer, including immunotherapies, targeted therapies, and novel hormone treatments, are improving patient outcomes. These innovations offer alternative approaches for patients whose cancer has become resistant to traditional therapies, contributing to the growth of the market as new and more effective treatment options become available.
- Increased Research and Development Investment: Pharmaceutical companies are investing heavily in research and development to discover new therapies for metastatic castration-resistant prostate cancer. This investment is leading to the introduction of innovative treatments that target specific genetic mutations or tumour markers, expanding the range of therapeutic options available to patients and driving market growth.
- Growing Awareness and Early Diagnosis: With increased awareness of prostate cancer and advances in diagnostic technology, more cases are being identified at earlier stages. However, despite early diagnosis and treatment, a significant proportion of patients still progress to metastatic castration-resistant prostate cancer, necessitating the development of advanced treatment strategies. This trend is driving demand for new therapeutic options that can effectively manage the disease at its later stages.
- Expanding Healthcare Infrastructure in Emerging Markets: As healthcare infrastructure improves in developing regions, there is increasing access to advanced cancer treatments, including those for metastatic castration-resistant prostate cancer. This expansion is creating opportunities for the growth of the market in emerging economies, where rising healthcare spending and a growing awareness of cancer treatment options are contributing to increased demand for effective therapies.
- High Cost of Treatment: The high cost of treatment for metastatic castration-resistant prostate cancer, particularly for newer therapies such as immunotherapy and targeted therapies, poses a significant challenge. Many patients, especially those in lower-income regions, may struggle to afford these treatments, which can limit access and slow the adoption of innovative therapies in certain markets.
- Treatment Resistance: A major challenge in the management of metastatic castration-resistant prostate cancer is the development of resistance to treatments. Over time, many patients with the disease become resistant to hormone therapy, chemotherapy, and other treatments, which limits the long-term effectiveness of available options and necessitates the development of new approaches to overcome treatment resistance.
- Adverse Side Effects of Therapies: Many treatments for metastatic castration-resistant prostate cancer, including chemotherapy and hormone therapies, can cause significant side effects, such as fatigue, nausea, and decreased immune function. These side effects can negatively impact patients' quality of life and may result in some patients opting to discontinue treatment, which poses a challenge for healthcare providers in managing the disease effectively.
- Limited Access to Advanced Therapies: In many developing countries, access to advanced therapies for metastatic castration-resistant prostate cancer is limited by insufficient healthcare infrastructure, high costs, and regulatory challenges. This lack of access to cutting-edge treatments can result in disparities in patient outcomes, with those in wealthier countries having greater access to life-saving therapies than those in poorer regions.
- Regulatory Challenges: The approval process for new cancer therapies is complex and highly regulated, requiring extensive clinical trials and evidence of safety and efficacy. These regulatory challenges can slow the pace of innovation and delay the introduction of new treatments for metastatic castration-resistant prostate cancer, making it difficult for pharmaceutical companies to bring novel therapies to market quickly.
- Development of Personalised Therapies: The rise of personalised medicine presents a significant opportunity in the metastatic castration-resistant prostate cancer market. By developing treatments tailored to individual patients' genetic profiles and tumour characteristics, pharmaceutical companies can offer more effective and targeted therapies, improving outcomes and extending survival rates for patients with this challenging condition.
- Expansion of Immunotherapy Applications: Immunotherapy is emerging as a promising treatment option for metastatic castration-resistant prostate cancer. As new immunotherapies demonstrate effectiveness in clinical trials, there is a growing opportunity to expand their use in treating this advanced form of prostate cancer. The development of immune checkpoint inhibitors and other immunotherapies could significantly enhance treatment outcomes for patients.
- Rising Focus on Combination Therapies: Combination therapies, which involve the use of multiple treatment modalities such as chemotherapy, immunotherapy, and hormonal therapy, are becoming an increasingly effective strategy for managing metastatic castration-resistant prostate cancer. The development of combination therapies that enhance the efficacy of existing treatments offers a major growth opportunity for pharmaceutical companies looking to improve patient outcomes.
- Emerging Markets Expansion: As healthcare infrastructure improves in emerging markets, there is an opportunity for pharmaceutical companies to expand their presence in these regions by offering advanced treatments for metastatic castration-resistant prostate cancer. Governments and private healthcare providers are investing in cancer care, creating new opportunities for market penetration in regions where access to advanced treatments has historically been limited.
The metastatic castration-resistant prostate cancer market is evolving rapidly, driven by technological innovations and advancements in treatment approaches. As ongoing research provides new insights into disease management and therapeutic strategies, several key trends are emerging that are shaping the future direction of this market. These trends are expected to significantly impact the treatment landscape, improving patient outcomes and expanding access to more effective and personalised therapies.
- Increased Adoption of Immunotherapy
- Growing Preference for Targeted Therapies
- Advancements in Precision Medicine
- Integration of Artificial Intelligence in Treatment Development
- Expansion of Clinical Trials for Novel Therapies
- Focus on Quality of Life Improvements
Metastatic Castration Resistant Prostate Cancer Market Segmentation
Market Breakup by Treatment Type
Chemotherapy
Immunotherapy
Hormonal Therapy
Radiation Therapy
Others
The market is segmented by treatment type into chemotherapy, immunotherapy, hormonal therapy, radiation therapy, and others. Chemotherapy and hormonal therapy remain the most commonly used treatments for metastatic castration-resistant prostate cancer. However, immunotherapy is gaining prominence as a targeted treatment with fewer side effects, while radiation therapy continues to be used in specific cases to manage pain and symptoms.
Market Breakup by Route of Administration
Oral
Parenteral
Others
The market is segmented by route of administration into oral, parenteral, and others. Oral administration is commonly used for hormonal therapies and some targeted treatments, providing convenience for patients undergoing long-term treatment. Parenteral administration, which involves injections or intravenous delivery, is used for chemotherapy and immunotherapy, ensuring faster and more controlled drug absorption.
Market Breakup by End User
- Hospitals
- Clinics
- Cancer Centers
- Research Laboratories
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Metastatic Castration Resistant Prostate Cancer Market Competitive Landscape
The competitive landscape of the metastatic castration-resistant prostate cancer market includes major players such as AstraZeneca, Pfizer Inc., AB Science, Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, Daiichi Sankyo Inc., Teva Pharmaceutical Industries Ltd, Sanofi, and Eli Lilly and Company. These companies are focused on developing innovative treatments, including immunotherapies and targeted therapies, with strategic partnerships and clinical trials driving market expansion.
Key Questions Answered in the Report
- What are the key drivers contributing to the growth of the metastatic castration-resistant prostate cancer market?
- How are advancements in immunotherapy impacting the treatment landscape for metastatic castration-resistant prostate cancer?
- What are the primary challenges facing pharmaceutical companies in developing new therapies for metastatic castration-resistant prostate cancer?
- How is the growing global incidence of prostate cancer influencing the demand for treatments for metastatic castration-resistant prostate cancer?
- What opportunities exist for the development of personalised therapies in the metastatic castration-resistant prostate cancer market?
- Which regions are expected to see the most significant growth in the metastatic castration-resistant prostate cancer market during the forecast period?
- How are precision medicine and genetic testing transforming the treatment of metastatic castration-resistant prostate cancer?
- What role do emerging markets play in the expansion of the metastatic castration-resistant prostate cancer market?
- How are collaborations between pharmaceutical companies and research institutions accelerating the development of new therapies for metastatic castration-resistant prostate cancer?
- What are the primary routes of administration for treatments for metastatic castration-resistant prostate cancer, and how do they vary by therapy type?
- How are clinical trials for novel therapies shaping the future of the metastatic castration-resistant prostate cancer market?
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the metastatic castration resistant prostate cancer market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the metastatic castration resistant prostate cancer market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the metastatic castration resistant prostate cancer industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Metastatic Castration Resistant Prostate Cancer Market Overview – 8 Major Markets
- 3.1 Metastatic Castration Resistant Prostate Cancer Market Historical Value (2018-2024)
- 3.2 Metastatic Castration Resistant Prostate Cancer Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Metastatic Castration Resistant Prostate Cancer Market Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Metastatic Castration Resistant Prostate Cancer Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 Germany
- 7.1.1.4 France
- 7.1.1.5 Italy
- 7.1.1.6 Spain
- 7.1.1.7 Japan
- 7.1.1.8 India
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 Germany
- 7.1.2.4 France
- 7.1.2.5 Italy
- 7.1.2.6 Spain
- 7.1.2.7 Japan
- 7.1.2.8 India
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 Germany
- 7.1.3.4 France
- 7.1.3.5 Italy
- 7.1.3.6 Spain
- 7.1.3.7 Japan
- 7.1.3.8 India
- 8 Metastatic Castration Resistant Prostate Cancer Market Landscape – 8 Major Markets
- 8.1 Metastatic Castration Resistant Prostate Cancer Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Metastatic Castration Resistant Prostate Cancer Market: Product Landscape
- 8.2.1 Analysis by Treatment Treatment Type
- 8.2.2 Analysis by Route of Administration
- 9 Metastatic Castration Resistant Prostate Cancer Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Metastatic Castration Resistant Prostate Cancer Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Metastatic Castration Resistant Prostate Cancer Market Segmentation (2018-2034) - 8 Major Markets
- 12.1 Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by Treatment Type
- 12.1.1 Market Overview
- 12.1.2 Chemotherapy
- 12.1.3 Immunotherapy
- 12.1.4 Hormonal Therapy
- 12.1.5 Radiation Therapy
- 12.1.6 Others
- 12.2 Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by Route of Administration
- 12.2.1 Market Overview
- 12.2.2 Oral
- 12.2.3 Parenteral
- 12.2.4 Others
- 12.3 Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by End User
- 12.3.1 Market Overview
- 12.3.2 Hospitals
- 12.3.3 Clinics
- 12.3.4 Cancer Centers
- 12.3.5 Others
- 12.4 Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by Country
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 United Kingdom
- 12.4.4 Germany
- 12.4.5 France
- 12.4.6 Italy
- 12.4.7 Spain
- 12.4.8 Japan
- 12.4.9 India
- 13 United States Metastatic Castration Resistant Prostate Cancer Market (2018-2034)
- 13.1 United States Metastatic Castration Resistant Prostate Cancer Market Historical Value (2018-2024)
- 13.2 United States Metastatic Castration Resistant Prostate Cancer Market Forecast Value (2025-2034)
- 13.3 United States Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by Treatment Type
- 13.3.1 Market Overview
- 13.3.2 Chemotherapy
- 13.3.3 Immunotherapy
- 13.3.4 Hormonal Therapy
- 13.3.5 Radiation Therapy
- 13.3.6 Others
- 13.4 United States Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by Route of Administration
- 13.4.1 Market Overview
- 13.4.2 Oral
- 13.4.3 Parenteral
- 13.4.4 Others
- 13.5 United States Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by End User
- 13.5.1 Market Overview
- 13.5.2 Hospitals
- 13.5.3 Clinics
- 13.5.4 Cancer Centers
- 13.5.5 Others
- 14 United Kingdom Metastatic Castration Resistant Prostate Cancer Market (2018-2034)
- 14.1 United Kingdom Metastatic Castration Resistant Prostate Cancer Market Historical Value (2018-2024)
- 14.2 United Kingdom Metastatic Castration Resistant Prostate Cancer Market Forecast Value (2025-2034)
- 14.3 United Kingdom Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by Treatment Type
- 14.3.1 Market Overview
- 14.3.2 Chemotherapy
- 14.3.3 Immunotherapy
- 14.3.4 Hormonal Therapy
- 14.3.5 Radiation Therapy
- 14.3.6 Others
- 14.4 United Kingdom Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by Route of Administration
- 14.4.1 Market Overview
- 14.4.2 Oral
- 14.4.3 Parenteral
- 14.4.4 Others
- 14.5 United Kingdom Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by End User
- 14.5.1 Market Overview
- 14.5.2 Hospitals
- 14.5.3 Clinics
- 14.5.4 Cancer Centers
- 14.5.5 Others
- 15 France Metastatic Castration Resistant Prostate Cancer Market (2018-2034)
- 15.1 France Metastatic Castration Resistant Prostate Cancer Market Historical Value (2018-2024)
- 15.2 France Metastatic Castration Resistant Prostate Cancer Market Forecast Value (2025-2034)
- 15.3 France Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by Treatment Type
- 15.3.1 Market Overview
- 15.3.2 Chemotherapy
- 15.3.3 Immunotherapy
- 15.3.4 Hormonal Therapy
- 15.3.5 Radiation Therapy
- 15.3.6 Others
- 15.4 France Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by Route of Administration
- 15.4.1 Market Overview
- 15.4.2 Oral
- 15.4.3 Parenteral
- 15.4.4 Others
- 15.5 France Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by End User
- 15.5.1 Market Overview
- 15.5.2 Hospitals
- 15.5.3 Clinics
- 15.5.4 Cancer Centers
- 15.5.5 Others
- 16 Italy Metastatic Castration Resistant Prostate Cancer Market (2018-2034)
- 16.1 Italy Metastatic Castration Resistant Prostate Cancer Market Historical Value (2018-2024)
- 16.2 Italy Metastatic Castration Resistant Prostate Cancer Market Forecast Value (2025-2034)
- 16.3 Italy Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by Treatment Type
- 16.3.1 Market Overview
- 16.3.2 Chemotherapy
- 16.3.3 Immunotherapy
- 16.3.4 Hormonal Therapy
- 16.3.5 Radiation Therapy
- 16.3.6 Others
- 16.4 Italy Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by Route of Administration
- 16.4.1 Market Overview
- 16.4.2 Oral
- 16.4.3 Parenteral
- 16.4.4 Others
- 16.5 Italy Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by End User
- 16.5.1 Market Overview
- 16.5.2 Hospitals
- 16.5.3 Clinics
- 16.5.4 Cancer Centers
- 16.5.5 Others
- 17 Spain Metastatic Castration Resistant Prostate Cancer Market (2018-2034)
- 17.1 Spain Metastatic Castration Resistant Prostate Cancer Market Historical Value (2018-2024)
- 17.2 Spain Metastatic Castration Resistant Prostate Cancer Market Forecast Value (2025-2034)
- 17.3 Spain Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by Treatment Type
- 17.3.1 Market Overview
- 17.3.2 Chemotherapy
- 17.3.3 Immunotherapy
- 17.3.4 Hormonal Therapy
- 17.3.5 Radiation Therapy
- 17.3.6 Others
- 17.4 Spain Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by Route of Administration
- 17.4.1 Market Overview
- 17.4.2 Oral
- 17.4.3 Parenteral
- 17.4.4 Others
- 17.5 Spain Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by End User
- 17.5.1 Market Overview
- 17.5.2 Hospitals
- 17.5.3 Clinics
- 17.5.4 Cancer Centers
- 17.5.5 Others
- 18 Japan Metastatic Castration Resistant Prostate Cancer Market
- 18.1 Japan Metastatic Castration Resistant Prostate Cancer Market Historical Value (2018-2024)
- 18.2 Japan Metastatic Castration Resistant Prostate Cancer Market Forecast Value (2025-2034)
- 18.3 Japan Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by Treatment Type
- 18.3.1 Market Overview
- 18.3.2 Chemotherapy
- 18.3.3 Immunotherapy
- 18.3.4 Hormonal Therapy
- 18.3.5 Radiation Therapy
- 18.3.6 Others
- 18.4 Japan Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by Route of Administration
- 18.4.1 Market Overview
- 18.4.2 Oral
- 18.4.3 Parenteral
- 18.4.4 Others
- 18.5 Japan Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by End User
- 18.5.1 Market Overview
- 18.5.2 Hospitals
- 18.5.3 Clinics
- 18.5.4 Cancer Centers
- 18.5.5 Others
- 19 India Metastatic Castration Resistant Prostate Cancer Market
- 19.1 India Metastatic Castration Resistant Prostate Cancer Market (2018-2034) Historical Value (2018-2024)
- 19.2 India Metastatic Castration Resistant Prostate Cancer Market (2018-2034) Forecast Value (2025-2034)
- 19.3 India Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by Treatment Type
- 19.3.1 Market Overview
- 19.3.2 Chemotherapy
- 19.3.3 Immunotherapy
- 19.3.4 Hormonal Therapy
- 19.3.5 Radiation Therapy
- 19.3.6 Others
- 19.4 India Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by Route of Administration
- 19.4.1 Market Overview
- 19.4.2 Oral
- 19.4.3 Parenteral
- 19.4.4 Others
- 19.5 India Metastatic Castration Resistant Prostate Cancer Market (2018-2034) by End User
- 19.5.1 Market Overview
- 19.5.2 Hospitals
- 19.5.3 Clinics
- 19.5.4 Cancer Centers
- 19.5.5 Others
- 20 Regulatory Framework
- 20.1 Regulatory Overview
- 20.2 US FDA
- 20.3 EU EMA
- 20.4 Japan PMDA
- 20.5 India CDSCO
- 20.6 Others
- 21 Patent Analysis
- 21.1 Analysis by Treatment Type of Patent
- 21.2 Analysis by Publication Year
- 21.3 Analysis by Issuing Authority
- 21.4 Analysis by Patent Age
- 21.5 Analysis by CPC Analysis
- 21.6 Analysis by Patent Valuation
- 21.7 Analysis by Key Players
- 22 Clinical Trials and Pipeline Analysis
- 22.1 Analysis by Trial Registration Year
- 22.2 Analysis by Trial Status
- 22.3 Analysis by Trial Phase
- 22.4 Analysis by Therapeutic Area
- 22.5 Analysis by Geography
- 22.6 Treatment Type Pipeline Assessment
- 23 Grants Analysis
- 23.1 Analysis by Year
- 23.2 Analysis by Amount Awarded
- 23.3 Analysis by Issuing Authority
- 23.4 Analysis by Grant Application
- 23.5 Analysis by Funding Institute
- 23.6 Analysis by NIH Departments
- 23.7 Analysis by Recipient Organization
- 24 Funding and Investment Analysis
- 24.1 Analysis by Funding Instances
- 24.2 Analysis by Treatment Type of Funding
- 24.3 Analysis by Funding Amount
- 24.4 Analysis by Leading Players
- 24.5 Analysis by Leading Investors
- 24.6 Analysis by Geography
- 25 Strategic Initiatives
- 25.1 Analysis by Partnership Instances
- 25.2 Analysis by Treatment Type of Partnership
- 25.3 Analysis by Leading Players
- 25.4 Analysis by Geography
- 26 Supplier Landscape
- 26.1 Market Share by Top 5 Companies
- 26.2 AstraZeneca
- 26.2.1 Financial Analysis
- 26.2.2 Product Portfolio
- 26.2.3 Demographic Reach and Achievements
- 26.2.4 Companies News and Developments
- 26.2.5 Certifications
- 26.3 Pfizer, Inc.
- 26.3.1 Financial Analysis
- 26.3.2 Product Portfolio
- 26.3.3 Demographic Reach and Achievements
- 26.3.4 Companies News and Developments
- 26.3.5 Certifications
- 26.4 AB Science
- 26.4.1 Financial Analysis
- 26.4.2 Product Portfolio
- 26.4.3 Demographic Reach and Achievements
- 26.4.4 Companies News and Developments
- 26.4.5 Certifications
- 26.5 Bristol Myers Squibb
- 26.5.1 Financial Analysis
- 26.5.2 Product Portfolio
- 26.5.3 Demographic Reach and Achievements
- 26.5.4 Companies News and Developments
- 26.5.5 Certifications
- 26.6 F-Hoffmann-La Roche Ltd
- 26.6.1 Financial Analysis
- 26.6.2 Product Portfolio
- 26.6.3 Demographic Reach and Achievements
- 26.6.4 Companies News and Developments
- 26.6.5 Certifications
- 26.7 Daiichi Sankyo Inc.
- 26.7.1 Financial Analysis
- 26.7.2 Product Portfolio
- 26.7.3 Demographic Reach and Achievements
- 26.7.4 Companies News and Developments
- 26.7.5 Certifications
- 26.8 Teva Pharmaceutical Industries Ltd
- 26.8.1 Financial Analysis
- 26.8.2 Product Portfolio
- 26.8.3 Demographic Reach and Achievements
- 26.8.4 Companies News and Developments
- 26.8.5 Certifications
- 26.9 Sanofi
- 26.9.1 Financial Analysis
- 26.9.2 Product Portfolio
- 26.9.3 Demographic Reach and Achievements
- 26.9.4 Companies News and Developments
- 26.9.5 Certifications
- 26.10 Eli Lily and Company
- 26.10.1 Financial Analysis
- 26.10.2 Product Portfolio
- 26.10.3 Demographic Reach and Achievements
- 26.10.4 Companies News and Developments
- 26.10.5 Certifications
- 27 Key Opinion Leaders (KOL) Insights (Additional Insight)
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- **The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.